Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.

Publication Type:

Journal Article


JAMA : the journal of the American Medical Association, Volume 299, Issue 9, p.1036-45 (2008)


2008, 258, Aged, Cardiovascular Diseases, Estrogen Replacement Therapy, Estrogens, Conjugated (USP), Female, Follow-Up Studies, Humans, Medroxyprogesterone Acetate, Middle Aged, Neoplasms, Risk Assessment


The Women's Health Initiative (WHI) trial of estrogen plus progestin vs placebo was stopped early, after a mean 5.6 years of follow-up, because the overall health risks of hormone therapy exceeded its benefits.